Drug Makers Stocks on Investors' Radar -- Depomed, United Therapeutics, DURECT, and Orexigen Therapeutics

Tuesday, January 31, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, January 31, 2017 /PRNewswire/ --

In today's pre-market research, Stock-Callers.com takes a closer look

at some Drug Manufacturers equities to see how they have fared at the close. Lined up for review today are: Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), DURECT Corp. (NASDAQ: DRRX), and Orexigen Therapeutics Inc. (NASDAQ: OREX).
These companies are part of the Healthcare sector which was moderately lower late Monday, January 30th, 2017, with the NYSE Health Care Index dropping about 0.5%, while shares of health care companies in the S&P 500 were down almost 0.6% as a group. Learn more about these stocks by downloading their comprehensive and free reports at:



Shares in Newark, California headquartered Depomed Inc. saw a drop of 1.22%, ending Monday's trading session at $17.74. The stock recorded a trading volume of 644,118 shares. The Company's shares are trading 7.09% below their 50-day moving average. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, has a Relative Strength Index (RSI) of 40.92. DEPO complete research report is just a click away and free at:


United Therapeutics  

Silver Spring, Maryland headquartered United Therapeutics Corp.'s stock declined 1.70%, closing the day at $159.67 with a total trading volume of 520,989 shares. The Company's shares have advanced 11.68% in the last one month, 37.24% in the previous three months, and 11.32% on an YTD basis. The stock is trading 12.96% above its 50-day moving average and 29.94% above its 200-day moving average. Additionally, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 66.31.

On January 19th, 2017, research firm Standpoint Research downgraded the Company's stock rating from 'Buy' to 'Hold'. The complimentary report on UTHR can be downloaded at:



On Monday, shares in Cupertino, California headquartered DURECT Corp. recorded a trading volume of 1.32 million shares, which was higher than their three months average volume of 544,970 shares. The stock ended the day 9.32% lower at $1.07. The Company's shares are trading below their 50-day moving average by 17.44%. Furthermore, shares of DURECT, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, has an RSI of 29.55.

On January 30th, 2017, DURECT provided an update on the DUR-928 development program. The Company's first patient trial utilizing DUR-928 was an open-label, single-ascending-dose safety and pharmacokinetic (PK) Phase-1b trial in liver function impaired (NASH) patients and matched control subjects. This study was conducted in Australia in successive cohorts evaluating single-dose levels of orally administered DUR-928. DURECT stated that an abstract for this study has been accepted and data from the study will be presented at the International Liver Congress™ 2017 organized by the European Association for the Study of the Liver in Amsterdam, April 19th-23rd, 2017. Sign up for your complimentary research report on DRRX at:


Orexigen Therapeutics  

La Jolla, California headquartered Orexigen Therapeutics Inc.'s stock dropped 1.20%, finishing yesterday's session at $3.30 with a total trading volume of 261,794 shares. The Company's shares have advanced 92.98% in the last one month, 10.74% in the previous three months, and 89.66% since the start of this year. The stock is trading above its 50-day moving average by 34.73%. Additionally, shares of Orexigen Therapeutics, which focuses on the development of pharmaceutical products, have an RSI of 59.19.

On January 25th, 2017, Orexigen Therapeutics announced that Laboratorios Farmace?uticos Rovi, S.A. has launched Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (?18 years) with an initial Body Mass Index (BMI) of ? 30 kg/m2, or ? 27 kg/m2 to < 30 kg/m2 in the presence of one or more weight-related co-morbidities. ROVI will market Mysimba as part of their diversified pharmaceutical portfolio under the terms of Orexigen Therapeutics' distributorship agreement signed in August 2016. Following a successful partnering process in 2016, Orexigen currently has commercialization arrangements with five different partners covering 38 countries. Get free access to your research report on OREX at:



Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store